The PRKAB2 antibody targets the β2 subunit of AMP-activated protein kinase (AMPK), a crucial energy-sensing enzyme conserved across eukaryotes. AMPK exists as a heterotrimer comprising α (catalytic), β (scaffolding), and γ (regulatory) subunits. PRKAB2 encodes the β2 isoform, which, along with β1 (PRKAB1), stabilizes the AMPK complex and influences tissue-specific localization and activation. While β1 is ubiquitously expressed, β2 predominates in skeletal muscle and cardiac tissue, suggesting distinct metabolic regulatory roles. Dysregulation of AMPK signaling, including β2 dysfunction, is linked to metabolic disorders (e.g., diabetes, obesity), cancer, and cardiovascular diseases. The PRKAB2 antibody is widely used in research to investigate AMPK’s β subunit expression, post-translational modifications, and interactions in cellular energy homeostasis. It aids in detecting protein levels via Western blotting, immunohistochemistry, or immunofluorescence, helping elucidate tissue-specific AMPK activity. Studies utilizing this antibody have revealed β2’s involvement in glucose uptake, lipid metabolism, and mitochondrial biogenesis, particularly in muscle during exercise or stress. Its application extends to exploring therapeutic targets, as AMPK activation via β2-associated pathways is a potential strategy for metabolic syndrome treatment. Validated antibodies ensure specificity for β2 over β1. critical given their structural similarities.